EMA, NCI, and EORTC agree on IBCD, a first of its kind meeting

(European Organisation for Research and Treatment of Cancer) The EORTC, the US National Cancer Institute, and the European Medicines Agency have signed an agreement to produce a first of its kind meeting to collaboratively explore current issues in cancer drug development. IBCD, Innovation and Biomarkers in Cancer Drug Development, will be held Dec. 3-4, 2015 at the Square Brussels Meeting Centre and convene the multiple cancer research stakeholders needed for effective cancer drug development.